Objectives: Optimal dosing for nebulized gentamicin is unknown. We compared the pulmonary and systemic pharmacokinetics (PK) of gentamicin following intravenous and nebulized administration in mechanically ventilated patients.
Introduction
Ventilator-associated pneumonia (VAP) is the most common complication due to mechanical ventilation and represents nearly half of all healthcare-associated infections, affecting 10%-27% of ventilated patients. 1, 2 In spite of a clear improvement in outcomes in the last two decades, VAP is still responsible for high mortality, ranging from 9%-13% in recent studies. 3 While VAP prognosis is linked to early effective antimicrobial therapy, poor lung tissue penetration of many antibiotics increases the risk of treatment failure. 4 Nebulization of antibiotics, by providing high intrapulmonary antibiotic concentrations with limited systemic exposure, 5 has shown promising results for VAP therapy in critically ill patients. 6, 7 Empirically used for decades, nebulized antibiotics are of particular interest for the delivery of hydrophilic antibiotics such as colistin [8] [9] [10] and aminoglycosides. 11 Aminoglycosides, after more than 50 years of use, still retain efficacy against many Gram-negative bacilli and Gram-positive cocci (including Staphylococcus aureus). 12 With their narrow therapeutic index 13 and poor lung penetration, 11, 14 aminoglycosides appear to be appropriate antibiotics for nebulization in combination with an intravenous b-lactam or glycopeptide. Gentamicin, which is particularly effective against Gram-positive cocci, is commonly used by nebulization to treat early VAP. 15 However, there is a lack of published data concerning the PK of gentamicin after nebulization and there is no consensus regarding the optimal use of this administration route. The efficacy of aminoglycosides has been linked to the ratio of the maximal concentration divided by the MIC (C max /MIC) of the pathogen. 16, 17 On the other hand, nephrotoxicity of gentamicin is correlated with the trough concentration in plasma (C min ), the range of C min that has been reported to be nephrotoxic being 0.5-4 mg/L. 18, 19 V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
The aim of this study was to compare pulmonary and systemic concentrations of gentamicin following intravenous administration and nebulization of 8 mg/kg gentamicin in critically ill patients with VAP.
Patients and methods

Study population
The study was conducted between October 2015 and November 2016 in 12 adult patients hospitalized in the surgical ICU of the University Hospital of Poitiers, France. Patients were eligible if they were !18 years of age and developed VAP due to gentamicin-susceptible pathogens and gentamicin treatment was justified. Patients were excluded if they had received aminoglycosides at any time during the 7 days preceding the study, had a CL CR ,60 mL/min, a BMI .40 kg/m 2 , poor respiratory function (PaO 2 /FiO 2 ,150) or a personal or family history of myasthenia.
At study onset, the following data were collected: age, sex, weight, height, diagnosis on admission, serum urea, serum creatinine, identification of pathogens, simplified acute physiology score (SAPS II) 20 and SOFA score. 21 CL CR was estimated according to the Modification of Diet in Renal Disease (MDRD) formula. 22 
Ethics
The study protocol was approved by the local ethics committee (Comité de Protection des Personnes Ouest III, approval number 2014-001665-27) and registered on ClinicalTrials.gov (number NCT02515448). Written informed consent was obtained for all patients from their nearest relatives prior to initiation of the study.
Gentamicin administration
Treatment was initiated with one 30 min intravenous infusion of 8 mg/kg gentamicin sulphate (Gentamicine Panpharma V R , Panpharma, Fougères, France) diluted in saline solution according to French guidelines. 23 A second intravenous infusion (same dose) was administered 24 h after the first dose if the plasma concentration of gentamicin was below 0.5 mg/L. At 48 h after the beginning of treatment, i.e. 24 or 48 h after the last intravenous dose, 8 mg/kg gentamicin was nebulized over 30 min using a vibrating mesh nebulizer (Aeroneb Pro V R , Aerogen, Galway, Ireland). During aerosol delivery, all patients were sedated and received volumecontrolled mechanical ventilation with a tidal volume of 7-8 mL/kg of predicted body weight and respiratory rates of 12-15 cycles/min. If the patient was ventilated with a heat and moisture exchanger, it was switched off and the circuit was changed. The nebulizer was inserted near the Y-piece connector on the inspiratory limb. During and within 1 h after the aerosol delivery, respiratory failure (defined by a decrease of .20% of PaO 2 /FiO 2 ) or bronchospasm (defined by the use of bronchodilatory therapy) were recorded.
Sampling procedures Blood samples
Blood samples were collected immediately before and 0.5, 1, 3, 5, 7, 10, 18 and 24 h after the first infused and nebulized gentamicin administration. They were immediately centrifuged at the bedside (3000 g for 10 min at 4 C) and the plasma was stored at #80 C pending assay.
Bronchoalveolar lavage fluid samples
Mini-bronchoalveolar lavage (BAL) was performed exactly as previously described. 9 Briefly, mini-BAL was performed with 16 Fr double sterile catheters (BAL, KimVent V R , Kimberly-Clark, Roswell, GA) inserted through the endotracheal tube. Two 20 mL aliquots of saline solution were instilled and then immediately aspirated with a syringe; these two BAL fluid samples were pooled and immediately centrifuged at the bedside (3000 g for 10 min at 4 C). Supernatants were stored at #80 C until analysis. For the first six patients, a mini-BAL was performed at 3 and 7 h after the beginning of the first intravenous infusion and after nebulization. For the last six patients, a mini-BAL was performed at 5 and 10 h after the beginning of the first intravenous infusion and after nebulization.
Urine samples
Urine samples were collected during the 24 h after the first intravenous infusion and after nebulization. At the end of the 24 h collection, the volume of urine was measured, urine was homogenized and a sample was stored at #80 C until analysis.
Gentamicin assay in plasma, BAL fluid and urine
A bioanalytical LC-MS/MS method was developed and validated to determine gentamicin concentrations in plasma, BAL and urine samples. The chromatographic analysis was carried out on an Alliance 1295 system (Waters), coupled to a triple quadrupole mass spectrometer, Quattro micro Api (Waters). Chromatographic separation was achieved on a C18 column (Waters XBridge BEH300, 150 mm % 2.1 mm, particle size 5 lM) using a Phenomenex Gemini as a pre-column. Gentamicin was separated using a mobile phase consisting of water and acetonitrile, both with 0.1% formic acid. Sisomicin was used as the internal standard (IS). Drugs were monitored using electrospray ionization operating in positive mode (ESI!) monitoring the transitions 478. 
Urea analysis in plasma and BAL fluid
A previously described LC-MS/MS assay was used for urea concentration measurements in BAL fluid samples. 8, 9 The limit of quantification of the assay was 1 mg/L in BAL fluid. Urea concentrations in plasma were measured by photometric detection using an automatic analyser (Modular automatic analyser; Roche, France; limit of quantification " 30 mg/L).
Estimation of gentamicin concentrations in epithelial lining fluid
Actual epithelial lining fluid (ELF) concentrations of gentamicin (C ELF ) were obtained from measured BAL fluid concentrations after correction for dilution, 24 according to the following equation:
where C BAL corresponds to the gentamicin concentration measured in BAL fluid, and Urea plasma and Urea BAL correspond to the concentrations of urea determined in plasma and BAL fluid, respectively. For the PK analysis, gentamicin concentrations in plasma, ELF and urine were analysed simultaneously. Model development was conducted with the first-order conditional estimation method (FOCE) with interaction. Several PK structural models were compared, including a model with nonrenal clearance of gentamicin since urine samples allowed discrimination of non-renal and renal clearances. Between-subject variability (BSV) and inter-occasion variability (IOV) for PK parameters were evaluated using an exponential model. Three distinct residual variabilities were estimated for plasma, ELF and urine concentrations. For each of them, additive, proportional and combined (additive ! proportional) models of error were explored. The relationships between gentamicin clearance and CL CR (estimated with the MDRD formula and capped at 130 mL/min as previously 25 ) and between the body weight and V were explored. 26 Discrimination between models was based on the inspection of graphical diagnostics and changes in the objective function value (OFV) provided by NONMEM. For a more complicated model to be retained it had to provide a significant improvement over the contending model (P , 0.05 for nested models) and provide parameter values with a good precision of estimation, i.e. with low relative standard error (RSE). In the case of non-nested models, Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) values were used to discriminate between models.
Population PK modelling
Model evaluation included graphical analysis of goodness-of-fit plots, RSEs, visual predictive checks (VPCs) and normalized prediction distribution errors (NPDE).
The final population PK model was used to simulate 10 000 individual concentration time courses. Simulations incorporated between-patient variability estimated with the final population PK model, but ignored parameter uncertainty. These simulations were used to estimate the distributions of the following secondary PK parameters: plasma C max values were obtained from individual simulations; plasma C min values were obtained from individual concentrations simulated 24 h after dosing; and plasma AUC 0-24 (AUC plasma ) and ELF AUC 0-24 (AUC ELF ) were calculated by integration of concentrations over time.
Results
Patients
A total of 12 men were enrolled. Their demographic, clinical and biological data are shown in Table 1 . Patient 12 was excluded from the study because of CL CR ,60 mL/min during the study.
Plasma and pulmonary PK
Five values of gentamicin concentration in ELF were removed from the analysis because the Urea BAL was lower than the limit of quantification. Plasma and ELF concentrations after administration of intravenous and nebulized 8 mg/kg gentamicin are shown in Table 2 .
The non-renal clearance of gentamicin was negligible, and thus the total clearance was considered equal to the renal clearance. Accordingly, from concentrations measured in urine, 24 h after intravenous infusion, most of the dose (82%) of gentamicin was excreted in urine. The structural PK model used to fit the data is presented in Figure 1 . Gentamicin was cleared from a central compartment (of volume V c ) by CL R , distributed towards a peripheral compartment with an intercompartmental clearance (Q plasma ) and towards ELF with an intercompartmental clearance (CL dif ). CL R was related to the CL CR of patients following the equation:
in which CL R, TV is the typical value of CL R for a patient with a CL CR of 110 mL/min and b is the exponent of the power function. V was Boisson et al.
not significantly related to body weight. In the lung, gentamicin was distributed between an ELF compartment (of volume V ELF ) and a peripheral compartment (of volume Vp lung ); Q lung refers to the intercompartmental clearance in the lung. After aerosol delivery, the fraction of the gentamicin dose that reached the ELF was defined as F AERO . Residual variabilities for plasma, ELF and urine concentrations were proportional. The addition of compartments, whether in the systemic or in the lung part of the model, the addition of a non-renal clearance, or the addition of clearances for active transport between plasma and lung did not significantly improve the data fit. PK modelling allowed a proper description of gentamicin concentrations in plasma, ELF and urine after intravenous administration and nebulization. The VPC showed that the model fitted the data without major bias (Figure 2 , data not shown for urine). The observed concentrations were evenly scattered around the typical profile and $6% of the observed data were outside the 90% predicted confidence intervals. Distributions of NPDE were close to Gaussian distribution (data not shown). The parameter estimates are presented in Tables 3 and 4 .
After intravenous administration the PK of gentamicin in plasma was biphasic with typical t1 =2 of the first and second phases of 1.9 and 7.5 h respectively. The distribution clearance between plasma and ELF (CL dif " 1.4 mL/h) was much lower than between plasma and the peripheral compartment (Q plasma " 19.3 mL/min). The median C max was predicted to be 29.6 mg/L and the median C min 0.24 mg/L, with 23% of patients predicted to have C min .0.5 mg/L. Concentrations measured in ELF after intravenous administration were in the same range as plasma concentrations (from 0.3 to 28 mg/L) and very variable between patients (Figure 2) .
Following gentamicin nebulization, gentamicin concentrations (expressed as AUC) were much higher ($4000-fold) in ELF than in plasma ( Figure 2 and Table 4 ). The systemic bioavailability of gentamicin was estimated to be 5%. Accordingly, from concentrations measured in urine, 24 h after nebulization, on average, 5.6% of the gentamicin dose was retrieved in urine. The PK of gentamicin in ELF was biphasic, with t1 =2 of the first and second phases of 0.3 and 7.3 h respectively. The peak in plasma occurred between 0.33 and 3 h after the start of nebulization, the typical C max and C min in plasma were predicted to be 0.50 and 0.07 mg/L respectively, with 3% of patients predicted to have C min .0.5 mg/L. The large variability of gentamicin concentrations observed in ELF after nebulization (from 1.6 to 25 290 mg/L) and after intravenous administration (from 0.3 to 28 mg/L) was characterized in the model by large inter-individual variabilities (IIVs) for intrapulmonary parameters (F AERO , V ELF and Vp lung , ranging between 127% and 155%) and large residual variability (105%). Compared with intravenous administration, after nebulization the exposure to gentamicin, as assessed by AUC, was 276-fold greater in ELF and 18-fold lower in plasma, on average (Table 4) .
Safety
During and after nebulization, no respiratory failure or bronchospasm occurred.
Discussion
The systemic and the lung parts of the PK model were both bicompartmental (Figure 1) . In our population with preserved renal Pharmacokinetics of intravenous and nebulized gentamicin JAC function, the typical renal clearance of gentamicin was 95 mL/min. V at steady-state was 29.9 L and the terminal t1 =2 was 7.5 h. These results were in agreement with those previously reported. 17 The diffusion of gentamicin between ELF and plasma was shown to have a unique distribution clearance, meaning that after intravenous administration AUCs of total concentrations in plasma and ELF were equal. This result has to be confirmed because of the high variability of gentamicin concentrations in ELF and of the early termination of BAL sampling (10 h). This is in accordance with passive diffusion of gentamicin if we assume that protein binding in plasma and tissue was similar. High protein binding of gentamicin within ELF could be responsible for high concentrations in ELF. Protein binding of gentamicin in plasma is known to be low (,30%) but binding in ELF is unknown. 27, 28 Only one study had been previously conducted to investigate gentamicin concentrations within ELF. Two hours after the start of a 30 min intravenous administration of 3.5 mg/kg gentamicin, gentamicin concentrations were about three times lower in ELF than in plasma, which is in accordance with our results at the same time (predicted ratio of 2.5).
14 However, after intravenous administration the peak of gentamicin in ELF was delayed and decreased compared with that in plasma, confirming that the rate of diffusion of gentamicin within ELF was slow. Therefore, the ratio measured at 2 h was lower than those observed later (Figure 2 ), indicating that a single measure in tissue might not be representative of tissue distribution over time. 29 It is notable that we ended BAL sampling 10 h after dosing; subsequent predictions of gentamicin concentrations should be considered with caution.
After nebulization, concentrations of gentamicin in ELF (as assessed by AUC) were $300-fold greater, on average, than after intravenous administration. Gentamicin concentrations in ELF were associated with high residual variability (105%). Such high residual variability had already been described in other studies, owing to BAL sampling, assay procedures and correction of BAL concentrations by the urea method. 9, 10, 30, 31 It is of note that in order to reduce the residual variability, in this study, sampling of ELF was done by mini-BAL, which is a reliable method compared with bronchoscopic BAL. 32 Moreover, the extremity of the catheter was protected, which reduced the contamination of the sample by gentamicin deposited on the trachea and stem bronchi. Moreover, it can be noted that after nebulization the variability of gentamicin concentrations in ELF was greater than after intravenous administration because of large IIVs of pulmonary parameters (Table 3 ). According to the PK model, the high concentrations measured in ELF were due to relatively slow passage of gentamicin from ELF to plasma (Q lung " 3.6 mL/h). This systemic passage was driven by the distribution of gentamicin within the lung and was biphasic, with a first phase t1 =2 of 0.3 h, explaining the early peak in plasma, and a second phase t1 =2 of 7.3 h. The poor permeation of gentamicin through physiological membranes is in accordance with its physicochemical properties since gentamicin is highly hydrophilic and polycationic at physiological pH (Log D " #12.4 and net charge of 5 at pH " 7.4) with a high polar surface area (199.7 Å 2 ). 33 The very high concentrations of gentamicin measured in ELF achieved with nebulization makes this a route of administration which attracts great interest. However, the level of gentamicin concentration in ELF necessary to be effective against pulmonary infections is unknown. The efficacy of aminoglycosides has been reported to be correlated with C max /MIC values greater than 7 to 10. 16, 17 However, these targets refer to plasma peak concentrations and their application to pulmonary concentrations may fail to predict aminoglycoside efficacy. 34 Indeed, plasma concentrations might poorly reflect activity of gentamicin in the lung because biofilms can slow the diffusion of aminoglycosides and because airway surface liquids contain proteins, such as mucin, to which aminoglycosides can bind, 35, 36 resulting in a dramatic decrease of their activity. [37] [38] [39] Concentrations needed in the lung to be effective might therefore be higher than in other sites of infection, thus reinforcing the interest in reaching high concentrations with nebulization. Pharmacokinetics of intravenous and nebulized gentamicin
JAC
We report for the first time the bioavailability of gentamicin after nebulization (F AERO ). On average, it was estimated to be 5%, which is consistent with the low bioavailabilities reported after nebulization of colistin or amikacin during mechanical ventilation. 9, 40 The IIV of F AERO was very large [coefficient of variation (CV) " 155%, 95% prediction interval " 0.7%-32.3%], resulting in a very variable AUC of gentamicin in plasma after nebulization. However, the aerosol delivery was standardized (sedation, ventilator parameters, ventilator circuit and settings) and some individual characteristics must be responsible for this large IIV. In a porcine model of pneumonia, it has been shown that pulmonary diffusion and systemic bioavailability of nebulized amikacin was influenced by experimental conditions, the severity of pneumonia and by the lung aeration. 5, 41, 42 The small number of patients enrolled limited the possibility of exploring this issue in more detail. Moreover, owing to the specific study population (exclusively composed of men and mainly trauma patients), the extension of our results to all critically ill patients should be done with caution.
Because of the low F AERO , plasma concentrations were much lower after nebulization of 8 mg/kg gentamicin than after intravenous administration. After nebulization, the typical C min in plasma was 0.07 mg/L (0.24 mg/L after intravenous) and only 3% (23% after intravenous) of patients were predicted to have C min .0.5 mg/L, which is usually considered a predictive limit value of the systemic toxicity of gentamicin. It is noteworthy that the nebulization was well-tolerated in every patient. However, the number of patients was not sufficient for an appropriate evaluation of safety and larger studies are warranted to address this issue.
Conclusions
Compared with intravenous administration, nebulization of gentamicin in patients with VAP provides higher pulmonary concentrations and lower systemic concentrations, but the IIV is large.
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